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Abstract
Gene expression studies indicate that body mass index (BMI) is associated with molecular 
pathways involved in inflammation, insulin-like growth factor activation, and other carcinogenic 
processes in breast tissue. The goal of this study was to determine whether BMI is associated with 
gene methylation in breast tissue and to identify pathways that are commonly methylated in 
association with high BMI. Epigenome-wide methylation profiles were determined using the 
Illumina HumanMethylation450 BeadChip array in the non-diseased breast tissue of 81 women 
undergoing breast surgery between 2009 and 2013 at the University of North Carolina Hospitals. 
Multivariable, robust linear regression was performed to identify methylation sites associated with 
BMI at a false discovery rate q value <0.05. Gene expression microarray data was used to identify 
which of the BMI-associated methylation sites also showed correlation with gene expression. 
Gene set enrichment analysis was conducted to assess which pathways were enriched among the 
BMI-associated methylation sites. Of the 431,568 methylation sites analyzed, 2573 were 
associated with BMI (q value <0.05), 57 % of which showed an inverse correlation with BMI. 
Pathways enriched among the 2573 probe sites included those involved in inflammation, insulin 
receptor signaling, and leptin signaling. We were able to map 1251 of the BMI-associated 
methylation sites to gene expression data, and, of these, 226 (18 %) showed substantial 
correlations with gene expression. Our results suggest that BMI is associated with genome-wide 
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methylation in non-diseased breast tissue and may influence epigenetic pathways involved in 
inflammatory and other carcinogenic processes.
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Introduction
Breast cancer is a heterogeneous disease composed of at least five subtypes based on gene 
expression patterns [1, 2]. The incidence of these breast tumor subtypes varies by risk 
factors such as age, race, body size, and breastfeeding history [3, 4], suggesting that risk 
factor status may differentially influence subtype-specific carcinogenic pathways. Obesity, 
in particular, is a modifiable breast cancer risk factor that has well-established and complex 
relationships with breast cancer subtypes [5, 6]. For example, though body mass index 
(BMI) is associated with increased risk of breast cancer subtypes that are both positive and 
negative for hormone receptors [6–10], the relationship may differ by menopausal status, 
with hormone receptor positive tumors associated with increased risk among 
postmenopausal, but decreased risk among premenopausal women [10, 11].
Gene expression studies suggest several mechanisms through which BMI might influence 
breast carcinogenesis. In studies of non-diseased breast tissue, differences in expression by 
BMI were found for genes that code for insulin-like growth factor 2 (IGF-2), for the insulin-
like growth factor 1 receptor (IGF-1R), and for genes involved in inflammation [12, 13]. 
When IGF-1R is triggered, it can activate many pathways that increase the proliferation of 
breast cells [14, 15] while an inflammatory response could contribute to tumor invasiveness 
through increased angio-genesis and tissue remodeling [16, 17]. It is unclear whether there 
are other mechanisms driving BMI-associated breast carcinogenesis.
The goal of this study, therefore, was to explore BMI-associated epigenetic changes in 
breast tissue using data from the Normal Breast Study. Specifically, we investigated whether 
BMI was associated with gene methylation in non-diseased breast tissue. Because gene 
methylation is a mechanism for controlling gene expression [18], we also assessed which of 
the BMI-associated methylation sites (methylation sites associated with BMI at a false 
discovery rate <0.05) were also correlated with gene expression. Identifying epigenetic 
changes that are associated with BMI and gene expression can provide insight into how BMI 
influences breast carcinogenesis and may direct research of molecular targets for the 
prevention of breast cancer.
Methods
Study population
Study subjects were participants in the Normal Breast Study. The study contacted 526 
English-speaking women, at least 18 years of age, undergoing breast surgery at University 
of North Carolina Hospitals between 2009 and 2013. The University of North Carolina at 
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Chapel Hill Institutional Review Board (IRB) approved this study and all participants 
provided informed consent according to an IRB-approved protocol.
Qualifying surgery types included total mastectomy, partial mastectomy, and excisional 
biopsy for women with breast tumors; prophylactic mastectomy for women at high risk of 
breast cancer; and reduction mammoplasty. Of the 526 patients contacted for participation, 
19 declined to participate, 4 requested removal from the study after providing written 
consent, and breast tissue was not available for 29 patients at the time of surgery, resulting 
in a final study population of 474 patients. Study participants provided breast tissue at the 
time of surgery. Samples with sufficient quantities were snap frozen. Patient demographic 
and risk factor data were collected through a telephone interview conducted by the 
University of North Carolina's Survey Research Unit. Medical abstraction was conducted to 
obtain anthropometric data.
Selection criteria for the present study included having an invasive ductal carcinoma with a 
tissue specimen sampled ≥4 cm from tumor margins, undergoing reduction mammoplasty, 
or undergoing prophylactic surgery. Of the 474 Normal Breast Study participants, 324 were 
diagnosed with invasive breast cancer and 150 participants had tissue collected that was >4 
cm from the tumor. Of the participants with tissue [4 cm from the tumor, 60 participants had 
a BMI ≥ 30 kg/m2, 45 had a BMI between 25 and 30 kg/m2, and 45 had a BMI < 25 kg/m2. 
Participants were randomly selected from each BMI group: 30 from the BMI ≥ 30 kg/m2 
group, 19 from the BMI between 25 and 30 kg/m2 group, and 21 from the BMI < 25 kg/m2 
group. All prophylactic surgery (n = 8) and reduction mammoplasty (n = 18) participants 
were included, resulting in a study population of 96. The tissue specimens for the 96 
participants were all snap frozen. Two adjacent 50 mg samples were taken from each of the 
participants’ tissue specimens: one portion was used for the methylation assessment; the 
second, adjacent sample was used for histology and to determine gene expression values.
The study sample was restricted to those of white or African–American race, resulting in the 
exclusion of 6 individuals of other race; current smokers were excluded from the dataset 
because only three individuals identified as such, as were two underweight (BMI < 18.5) 
individuals and four individuals missing data on alcohol use. The resulting final study 
population was 81.
Gene methylation assessment
The Illumina HumanMethylation450 BeadChip array [19] was used to measure methylation 
levels in the tissue samples. The array assesses methylation at 485,577 cytosine-guanine 
dinucleotide (CpG) sites and has a coverage of 99 % of RefSeq genes, with an average of 17 
CpG sites per gene. DNA was isolated using the DNeasy Blood and Tissue Kit from Qiagen 
(Valencia, CA) by following the manufacturer's spin-column protocol. Sodium bisulfite 
modification of the DNA was conducted using EZ DNA Methylation Gold Kit (Zymo 
Research, Orange, CA), after which the quantity and concentration of the DNA were 
assessed using a Nanodrop spectrophotometer to ensure that 500 ng of DNA was available 
for use for the HumanMethylation450 BeadChip platform.
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Methylation levels (beta values) were calculated based on the intensity measures for 
unmethylated (U) or methylated (M) CpGs. Probe raw intensity values were extracted with 
the Illumina GenomeStudio® software (version 2011.1). To correct dye bias and normalize 
the methylation data, the M and U intensity values were pre-processed separately for the 
Infinium I and II CpG probes as follows: (1) for Infinium I probes, the red and green 
channel probes were separately background corrected (using the Robust Multichip Average 
(RMA) method [20]) and quantile normalized; (2) for Infinium II probes, dye bias between 
U and M intensity values were first corrected using the normalizeMethyLumiSet method in 
the R package “methylumi” [21], and then RMA background correction and quantile 
normalization were performed separately for U and M intensity values; (3) the beta value for 
each CpG site was recalculated as the ratio of normalized fluorescent intensities between 
methylated and unmethylated alleles β = M/(M + U + 100); a beta value of 0 indicates no 
methylation while a value of 1 indicates complete methylation. Batch effects and bisulfite 
conversion intensities were adjusted for and, to minimize the effect of outlier methylation 
values in regression modeling, any beta values that were more than three standard deviations 
from the mean were excluded for each CpG probe. Low performance CpG probes were also 
filtered by (1) excluding 13,449 CpG probes located at sites with common SNPs (minor 
allele frequency ≥0.05 in Europeans or Africans based on the 1000 Genomes Project data 
[22]); and (2) excluding 41,937 CpGs with probes mapped to multiple genomic locations 
[23]. After applying these exclusion criteria, 431,568 CpGs remained. The array data have 
been deposited in Gene Expression Omnibus under accession number GSE67919.
Gene expression assessment
Gene expression was assessed in frozen tissue samples adjacent to the tissue sampled for the 
methylation assay. RNA was isolated using Qiagen RNeasy kits (Valencia, CA). A 
Nanodrop spectrophotometer and an Agilent 2100 Bio-analyzer were used to assess RNA 
concentration and quality, respectively. Gene expression analysis was performed using 
Agilent Low Input Quick Amp labeling, 2-color (5190-2306) and Human Gene Expression 4 
× 44 k v2 Microarray kits (G4845A; Santa Clara, Ca) as per the manufacturer's instruction. 
The data were normalized and probes with <10 dpi in any channel were excluded [13]. 
Probes with missing data for more than 20 % of the samples, probes that did not map to an 
ENTREZ ID, or individuals missing data for more than 30 % of probes were also excluded.
Statistical analysis
Robust linear regression, in which parameter estimates are less influenced by outliers, was 
used to assess the relationship between BMI and gene methylation [24]. BMI at the time of 
surgery was treated as a continuous linear variable for regression modeling. Age at first 
pregnancy, parity, menopausal status, alcohol use, physical activity, and fruit and vegetable 
intake were assessed for confounding. Only ever alcohol use (≥12 lifetime drinks) met our 
empirical criteria for confounding (association with BMI at p value <0.05 and association 
with gene methylation at false discovery rate (FDR) q value <0.05 [25]). The final 
adjustment set consisted of alcohol use, along with age and race, which were determined to 
be confounders a priori. A CpG site was considered BMI-associated if it was associated with 
BMI at a false discovery rate q value of <0.05.
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Linear regression was also used to determine which of the BMI-associated CpG sites were 
correlated with gene expression. Correlation between gene methylation and expression was 
evaluated for 61 of the 81 study participants (20 participants were excluded after applying 
the gene expression quality control criteria described above). All statistical analyses were 
performed using the R software package (version 2.15.3). An FDR q value of <0.05 was 
used as the significance cut-off for regression analyses; a Pearson correlation cut-off of ≤–
0.30 or ≥0.30 was used as the criteria for determining correlation with gene expression.
Gene set enrichment analysis was conducted to determine what pathways were enriched 
among the BMI-associated methylation sites. Using data from the National Center for 
Biotechnology Information (NCBI) Human Genome Build 37 Gene Annotation Database 
[26], each CpG was mapped to the nearest gene based on distance between the CpG and a 
nearby gene transcription start site (TSS). A total of 392,910 CpGs on the array are within 5 
kb of the nearest TSS of 22,810 NCBI reference genes. CpGs located farther than 5 kb from 
the nearest TSS were excluded from the gene set enrichment analysis. To test for enrichment 
of gene pathways in BMI-associated CpG sites, Ingenuity Systems Pathway Analysis (IPA, 
Ingenuity® Systems, www.ingenuity.com) was used, though IPA analysis is limited by the 
calculation of p-values using a gene-sampling rather than subject-sampling framework [27]. 
We first identified all 640 canonical pathways that included at least one of the 22,810 genes 
represented on the array from the IPA web server, then a binomial test was performed to test 
whether genes significant at a FDR threshold of 0.05 were enriched in any of these 
pathways. Enrichment test p values were derived from 5000 rounds of permutation tests. At 
each permutation test, association test p values were randomly shuffled for all 392,910 CpGs 
and then repeated for each corresponding enrichment test. A permutation p value of <0.05 
was used as a significance cut-off. We also conducted permutation-based IPA analyses on 
the BMI-associated sites identified in two studies [13, 28] that examined the association 
between BMI and gene expression in breast tissue.
Results
The 81 study participants ranged in age from 19 to 84 years, with a median age of 53. 
Approximately 27 % of the study participants were normal weight (18.5 kg/m2 ≥ BMI > 25 
kg/m2), 32 % were overweight (25 kg/m2 ≥ BMI > 30 kg/m2), and 41 % were obese (BMI ≥ 
30 kg/m2) (Table 1). An exploratory analysis was conducted to examine the effect of tissue 
source (reduction mammoplasty, prophylactic surgery, or invasive ductal carcinoma) on 
methylation value to determine whether it was appropriate to analyze these distinct tissue 
sources together. In the analysis, tissue source was treated as the main exposure variable and 
age was a covariate. No methylation sites were significantly associated with tissue source in 
this analysis, indicating that the three tissue sources could be analyzed together.
Robust linear regression analyses revealed that 2,573 CpG sites were significantly 
associated with BMI at FDR q value <0.05 after adjustment for age, race, and alcohol use 
(Supplemental Table 1). BMI-associated methylation sites were found on all chromosomes 
(Fig. 1), and approximately 57 % of the sites were inversely associated with BMI. Figure 2 
displays scatterplots of methylation values by BMI for selected CpG sites to provide visual 
representations of the association between BMI and gene methylation. Of the 2573 BMI-
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associated probes, 10 % were located on CpG islands, which are often near promoter regions 
[29], 24 % were located on shores, which are up- or downstream of CpG islands [30], and 
11 % were located on shelves, which are up- or downstream of shores [30]; the remaining 54 
% were not located in or near CpG islands. The BMI-associated probes in this analysis were 
less likely to be located on CpG islands than would be expected based on the representation 
of CpG island probes on the 450 k platform (10 % vs 31 %) (Chi square p value <0.001).
Based on gene set enrichment analysis using the IPA database, many of the BMI-associated 
methylation sites were involved in inflammatory or immune response pathways, including 
genes indicated in the signaling of several interleukins, natural killer cells, B cells, T cells, 
and NF-kB (Supplemental Table 2). Metabolic pathways involving insulin receptor and 
leptin signaling and pathways that influence carcinogenesis, such as human epidermal 
growth factor 2 (HER-2), angiopoietin, and hepatocyte growth factor (HGF) signaling, were 
also significantly associated (permutation p value <0.05) with the BMI-associated CpG sites. 
The pathways identified from our BMI-associated methylation sites were also identified in 
two previously reported gene expression studies [13, 28] listed in Table 2. Many of the 
common pathways were related to inflammatory processes, though there were also pathways 
indicative of cardiovascular pathogenesis, such as the aldosterone signaling in epithelial 
cells pathway and the endothelin-1 signaling pathway. One gene, C-terminal binding protein 
2 (CTBP2), was associated with BMI in all three studies (Supplemental Table 3); the 
association between BMI and methylation percentage for the CTBP2 probe identified in this 
study is shown in Fig. 2b.
Of the 2573 BMI-associated probes, 1251 mapped to loci with gene expression data on the 
microarray dataset. Of those 1251 sites, 226 were correlated with gene expression at a 
Pearson correlation coefficient equal to or greater than the absolute value of 0.30 
(Supplemental Table 4). Of these 226 CpGs, 68 % showed an inverse relationship between 
proportion of methylation and level of gene expression. CpG sites that were on shores were 
more likely to be correlated with gene expression than CpG sites that were on islands, 
though the difference was not statistically significant (18 vs. 12 %; Chi square p value = 
0.14).
Discussion
This is the first study to examine the association between BMI, genome-wide methylation, 
and gene expression in histologically non-diseased breast tissue. Pathways enriched among 
the 2573 BMI-associated sites included those involved in inflammation, insulin receptor 
signaling, and leptin signaling. Approximately 18 % (226/1251) of the BMI-associated 
methylation sites that were near gene TSS were significantly associated with gene 
expression. Similar to other research, we found that correlation with expression was higher 
for probes located on CpG shores than for probes located on CpG islands [30, 31]. The 
lower correlation between methylation and expression in islands relative to shores may be 
because methylation acts to repress gene expression through promotion of histone 
modification more than through interference with transcription binding on promoter regions 
[32].
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It has been hypothesized that BMI may influence breast carcinogenesis through multiple 
mechanisms [12–15], and our data are consistent with these hypotheses. Our observation 
that BMI-associated methylation occurred preferentially in genes involved in inflammatory 
response (e.g., interleukin-6 and NF-kappaB signaling), energy metabolism (insulin receptor 
and leptin signaling), and epithelialstromal interactions (hepatocyte growth factor signaling) 
is in line with previous mechanistic research [15, 33–37]. Interleukin-6 (IL-6), a product of 
chronic inflammation, is associated with obesity and has both cancer-promoting and anti-
cancer functions [33–35]. Although IL-6 has been associated with decreased risk of early-
stage breast cancer, the cytokine is also correlated with cell migration, anti-apoptosis, 
stimulation of aromatase activity, and poor prognosis among those with metastatic disease 
[14, 38, 39]. The activation of NF-kB signaling is associated with angiogenesis, tumor 
invasiveness, and anti-apoptosis in tumor cells [36] while a pathway involving the signaling 
of leptin, a ligand produced by adipose tissue, could influence breast carcinogenesis through 
increased estrogen production via aromatase transcription [40, 41] and also through the 
promotion of angiogenesis and tumor invasion [5, 42]. Insulin-like growth factor receptor 
signaling involves activation of pathways shown to increase proliferation of breast cells [14, 
15] while hepatocyte growth factor (HGF) has been shown to be associated with obesity in 
murine models [37], to promote cell migration in vitro [37], and to influence the invasive 
potential of premalignant breast cells [43]. Although these pathways identified among our 
BMI-associated methylation sites suggest a potential role for BMI in cancer-related 
methylation changes, it is unknown whether these changes induce a direct effect on 
epithelial cells.
Our results are consistent with studies finding that BMI is associated with gene expression 
changes in breast tumor tissue. Creighton et al. reported that 799 probes representing 662 
genes were differentially expressed when comparing the breast tumor tissue of obese 
patients to that of normal and overweight patients [28]. We compared the BMI-associated 
genes present in our study with those listed by Creighton et al. to identify which genes were 
on both lists, and therefore may be good candidates for further scientific exploration. We 
were able to examine the overlap between 439 of the 662 genes listed by Creighton et al. 
and found that 42 genes were identified in both studies (Supplemental Table 3). Similarly, in 
our previous work examining the tissue from women undergoing reduction mammoplasty 
from a different population, we found 760 genes were differentially expressed when 
comparing the non-diseased tissue of obese and normal weight women [13]; we were able to 
examine the overlap between 547 of those 760 genes and found that 68 of them were 
identified in both studies (Supplemental Table 3). As in our present study, we previously 
reported enrichment for pathways involved in inflammation and immune response, including 
pathways that may act in macrophage infiltration [13]. Furthermore, one gene, CTBP2, 
which encodes for a transcriptional repressor, was identified as associated with BMI in our 
present methylation-based analysis, in our previous gene expression results [13], and in the 
gene expression results of Creighton et al. [28]. Expression of members of the CTBP family, 
which has been shown to promote the epithelial to mesenchymal transition and genomic 
instability in breast cancer cells [44], has been implicated in breast carcinogenesis [44, 45].
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Our findings of a significant association between BMI and gene methylation are in contrast 
to the results of several previous studies that examined the relationship between BMI and 
methylation of specific candidate genes. These studies evaluated either non-diseased or 
tumor breast tissue, but did not find any significant associations [46, 47]. However, these 
studies were limited by small strata [47] and did not use a genome-wide approach [46, 47].
Our work was strengthened by studying epigenetic changes in benign breast tissue, which 
has more genomic stability than tumor tissue [48]. Methylation patterns may change after 
cancer initiation in tumor tissue, so studying the benign tissue allows assessment of 
pathways more proximal to exposure. Nonetheless, it is possible that these tissues harbor 
some changes related to the disease status of the patients, limiting the generalizability of our 
results. However, the use of tissue sampled >4 cm from an invasive tumor should minimize 
the potential effects of field cancerization [49–51]. Also, the inclusion of reduction 
mammoplasty patients with no disease and the observation in an exploratory analysis that 
methylation patterns were not different by tissue source in this population further mitigate 
this concern. This study was also strengthened by studying both methylation and expression 
in the same patients, allowing us to examine the extent to which differences in methylation 
were associated with differences in gene expression.
Our study identified numerous BMI-associated changes in normal breast tissue. Our results 
suggest that adiposity influences the epigenetic profile of breast tissue. BMI may affect the 
cellular microenvironment or breast epithelial cells through several different cancer-
associated pathways. As it is unknown whether these epigenetic changes are reversible with 
weight loss, future research might evaluate methylation in these same pathways following 
weight loss and gain. Molecular markers of obesity's effects on breast tissue are important 
for elucidating the biologic pathways driving breast tumorigenesis and may increase our 
ability to prevent and treat breast cancer.
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Manhattan plot of body mass index association p values, sorted by chromosome location. 
Dashed line indicates false discovery rate cut-off of <0.05
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a Four scatterplots of methylation level by body mass index for selected probes. b 
Scatterplot of methylation level by body mass index for probe ID cg06332304 on the 
CTBP2 gene
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Table 1
Selected population characteristics in the Normal Breast Study
N
.Total 81 100
Body Mass Index (BMI)
    Obese (BMI ≥ 30) 33 41
    Overweight (25 ≤ BMI < 30) 26 32
    Normal (18.5 ≤ BMI < 25) 22 27
Race
    White 55 68
    African–American 26 32
Age
    Age < 50 31 38
    Age ≥ 50 50 62
Menopausal status
    Premenopausal 27 33
    Postmenopausal 50 62
    Missing 4 5
Ever consumed alcohol
    Yes 66 81
    No 15 19
Tissue Source
    Prophylactic surgery 6 7
    Reduction mammoplasty 17 21
    Mastectomy/lumpectomy 58 72
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